ProMetic Life Sciences Inc. (TSE:PLI) had its target price boosted by stock analysts at National Bank Financial from C$2.00 to C$2.50 in a research note issued on Wednesday. National Bank Financial’s price objective would suggest a potential upside of 66.67% from the company’s current price.

Other research analysts have also issued reports about the company. Canaccord Genuity reduced their target price on ProMetic Life Sciences from C$4.75 to C$4.50 and set a “buy” rating on the stock in a research report on Monday, June 19th. Scotiabank reduced their target price on ProMetic Life Sciences from C$4.75 to C$4.00 and set an “outperform” rating on the stock in a research report on Friday, July 7th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of ProMetic Life Sciences in a research report on Wednesday, May 24th. Finally, TD Securities reduced their target price on ProMetic Life Sciences from C$4.50 to C$3.50 and set a “speculative buy” rating on the stock in a research report on Wednesday, August 16th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of C$3.60.

ProMetic Life Sciences (TSE:PLI) traded up 12.00% during mid-day trading on Wednesday, hitting $1.68. 4,202,944 shares of the stock traded hands. ProMetic Life Sciences has a 52-week low of $1.12 and a 52-week high of $3.24. The firm’s 50-day moving average is $1.48 and its 200 day moving average is $1.96. The firm’s market cap is $1.19 billion.

WARNING: This news story was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.watchlistnews.com/prometic-life-sciences-inc-pli-pt-raised-to-c2-50/1532246.html.

In other news, Director Louise Ménard sold 82,202 shares of the stock in a transaction dated Monday, July 10th. The stock was sold at an average price of C$1.60, for a total value of C$131,523.20. Also, insider Patrick Sartore sold 64,579 shares of the stock in a transaction dated Thursday, August 24th. The shares were sold at an average price of C$1.15, for a total value of C$74,265.85. Over the last three months, insiders bought 98,250 shares of company stock worth $129,269 and sold 179,102 shares worth $242,635.

About ProMetic Life Sciences

Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Analyst Recommendations for ProMetic Life Sciences (TSE:PLI)

Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.